Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Use of Blood Biomarkers to Predict Overall Survival for Non-Small-cell Lung Cancer (NSCLC) Patients Treated With (Chemo)Radiotherapy.

NCT01936571 is registered in ClinicalTrials.gov with Maastricht Radiation Oncology as lead sponsor.

NCT NCT01936571
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01936571 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Use of Blood Biomarkers to Predict Overall Survival for Non-Small-cell Lung Cancer (NSCLC) Patients Treated With (Chemo)Radiotherapy.
Lead sponsor
Maastricht Radiation Oncology
Phase
Observational
Overall status
Completed
Start date
September 30, 2013
Completion date
March 31, 2014
Enrollment
250 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer